Anti-Ly49C (Clone 4LO3311) – FITC

Anti-Ly49C (Clone 4LO3311) – FITC

Product No.: L311

[product_table name="All Top" skus="D353"]

- -
- -
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
Ly-49 inhibitory receptors C
IgG3 κ

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Host Species
Product Concentration
0.2 mg/ml
This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
This Fluorescein conjugate is stable when stored at 2-8°C. Do not freeze.
Country of Origin
Next Day 2-8°C
Excitation Laser
Blue Laser (490 nm)
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


4LO3311 activity is directed against Ly49C (Killer cell lectin-like receptor 3, KLRA3; NK2.1). 4LO3311 binds an epitope located in a 32-amino acid segment of the stalk region immediately adjacent to the carbohydrate recognition domain.
Ly49 receptors are homodimeric type II C-type lectin-like membrane glycoproteins encoded by a family of highly polymorphic genes in the mouse natural killer (NK) gene complex1. Ly49 receptors recognize class I major histocompatibility complex-I (MHC-1) and MHC-1 like proteins. Ly49C is an inhibitory member of the Ly-49 superfamily. Inhibitory Ly49 receptors are involved in NK cell education1 and play a role in controlling viral infection2. Additionally, Ly49C decreases the activation threshold of NK cells by inhibiting H2-Kb 3. Ly49C is expressed on NK, uterine NK, NKT, and CD8+ Tregs cells1. Ly49C is closely related to Ly49F, Ly49I, and Ly49H3. 4LO3311 was generated by immunizing 129/SvJ mice with C57BL/6 NK-enriched spleen cells4. Hybridoma lines were prepared by fusing immune spleen cells with non-secreting P3X63-Ag8.653 myeloma cells and subsequently screened for production of anti-NK antibodies. Isotype was determined by double-immunodiffusion analysis of hybridoma supernatants using rabbit monospecific anti-mouse immunoglobulins. 4LO3311 is of IgG3, κ isotype. 4LO3311 recognizes an epitope located in a 32-amino acid segment of the stalk region immediately adjacent to the carbohydrate recognition domain5. 4LO3311 recognizes Ly-49CBALB but not Ly-49AB6, Ly-49ABALB, BBALB, DB6, EB6, FB6, GB6, GBALB, or H. 4LO3311 plus complement inhibits NK cell and antibody-dependent cellular cytotoxicity (ADCC) activity in C3H spleen cells4. 4LO3311 inhibits C57BL/6 and C3H NK cell activity but has no effect on NZB NK cells.
Antigen Distribution
Ly49C is expressed on NK, uterine NK, NKT, and CD8+ T cells.

Antigen Details

Research Area

References & Citations

1. Rahim MM, Tu MM, Mahmoud AB, et al. Front Immunol. 5:145. 2014.
2. Parikh BA, Bern MD, Piersma SJ, et al. Cell Rep. 32(4):107969. 2020.
3. Schenkel AR, Kingry LC, Slayden RA. Front Immunol. 4:90. 2013.
4. Lemieux S, Ouellet-Talbot F, Lusignan Y, et al. Cell Immunol. 134(1):191-204. 1991.
5. Brennan J, Lemieux S, Freeman JD, et al. J Exp Med. 184(6):2085-2090. 1996.
6. Hsu J, Hodgins JJ, Marathe M, et al. J Clin Invest. 128(10):4654-4668. 2018.
7. Depatie C, Chalifour A, Paré C, et al. Int Immunol. 11(9):1541-1551. 1999.
Flow Cytometry

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.